There are currently 436 clinical trials in Kansas City, Missouri looking for participants to engage in research studies. Trials are conducted at various facilities, including Children's Mercy Hospital, Research Medical Center, Saint Luke's Hospital of Kansas City and CCOP - Kansas City. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Kansas City Research Institute, Kansas City, Missouri
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
ADPKD Patient Registry
NCT04039061
Recruiting
The purpose of the ADPKD Registry is to create an online patient network that includes at least 5,000 people with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who contribute data on their health and other topics. The ADPKD Patient Registry aims to support important scientific discoveries and support patient needs in the following ways: * Connect ADPKD patients with opportunities to join clinical studies. * Collect data for the research community to better describe the ADPKD disease expe... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/15/2023
Locations: PKD Foundation, Kansas City, Missouri
Conditions: Polycystic Kidney Diseases
Register for Updates
Group CBT in Parents of Children With Food Allergy
NCT06138431
Recruiting
Parents of children with food allergies that are medically established will be randomized to participate either in 6 one-hour weekly virtual Cognitive Behavioral Therapy (CBT) groups or to a wait-list group, and outcomes will be measured for anxiety, depression and quality of life. Possible benefits include improvement in psychological functioning and quality of life of families, as well as improved understanding of the use of group Cognitive Behavioral Therapy (CBT) for parents of children with... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: University Health Behavioral Health Canvas Building, Kansas City, Missouri
Conditions: Parents
Register for Updates
Treatment of PAF With the Synaptic System
NCT05905835
Recruiting
Enrolled subjects will be treated with the Synaptic Cryoablation System. Treatment will include cryoablation of the pulmonary veins to achieve PVI. All subjects will be followed for twelve (12) months after completion of the index ablation procedure.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/09/2023
Locations: St. Luke's Mid America, Kansas City, Missouri
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT04725383
Recruiting
The investigators will recruit 30 children and adolescents (15 per group x 2 groups) aged 6 to 17 years with ASD and significant repetitive behaviors that cause problems to them and to others around them. Subjects will be randomized to either amitriptyline (AMI), dosed flexibly according to response and tolerability with a maximum dose of 100mg per day or 1.5mg/kg/day, in divided doses to minimize side effects, or placebo in look-alike capsules, for 10 weeks. Rating scales will be used to measur... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
11/02/2023
Locations: University Health Behavioral Health Canvas Building, Kansas City, Missouri
Conditions: Autism Spectrum Disorder, Repetitive Compulsive Behavior
Register for Updates
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
NCT04467801
Recruiting
For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy. This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: The University of Kansas Cancer Center, North Clinic, Kansas City, Missouri
Conditions: NSCLC Stage IV, NSCLC Stage IIIB
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 5, Kansas City, Missouri
Conditions: FSGS
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Alliance for Multispecialty Research, LLC, Kansas City, Missouri +1 locations
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
Examining the Effect of Eye Gaze Technology on Children With Cortical Visual Impairment
NCT06067607
Recruiting
The goal of this study is to learn about eye gaze technology's use as an assessment and intervention of visual skills and the impact on occupational performance in children with cortical/cerebral visual impairment. The main questions the study aims to answer are: Does the use of eye gaze technology with graded visual activities improve visual abilities: Does an improvement in visual abilities improve occupational performance? - What are the factors that correlate with improved visual abilities?... Read More
Gender:
All
Ages:
Between 2 years and 10 years
Trial Updated:
10/02/2023
Locations: The Children's Center for the Visually Impaired, Kansas City, Missouri
Conditions: Cortical/Cerebral Visual Impairment, Cerebral Palsy
Register for Updates
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Alliance for Multispecialty Research, LLC, Kansas City, Missouri
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Register for Updates
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
NCT02302742
Recruiting
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2023
Locations: Truman Medical Center, Kansas City, Missouri +3 locations
Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Register for Updates
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT05143229
Recruiting
This study evaluates the safety and efficacy of sacituzumab govitecan plus alpelisib for treatment of metastatic or locally recurrent HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2023
Locations: The University of Kansas Cancer Center - North Kansas City Hospital, Kansas City, Missouri +1 locations
Conditions: Breast Cancer
Register for Updates